Cancer
Almost 300 participants gathered for the Run the Runway fundraiser at Inverness Airport, completing a 5km run under the stars to raise funds for Maggie's Highlands, a charity that provides practical and emotional support for those facing cancer treatment and their loved ones. The unique event, which took
Cancer
Scientists at Instituto de Salud Carlos III have made a significant breakthrough in cancer gene therapy, successfully targeting Ewing sarcoma cells using GGAA promoters and adenoviral vectors. This innovative approach involves expressing the suicide gene thymidine kinase from herpes simplex virus (HSV-TK) in Ewing sarcoma cells, leading to cell death
Cancer
The University Hospitals of Leicester NHS Trust has gained approval for its plans to expand the Leicester Royal Infirmary, with a new floor added to the existing building to accommodate an aseptic pharmacy and increased capacity for cancer treatments. The expansion aims to address the growing demand for cancer services
Cancer
CancerIQ, a healthcare technology company, is addressing a critical gap in cancer risk assessment by providing patients with "hyper-personalized" patient education, engagement, and navigation support. The company's focus is on helping patients take the next crucial step in cancer prevention, particularly in identifying those at high
Cancer
Researchers at Nanjing University of Posts and Telecommunications in Nanjing, People's Republic of China, have discovered that amlodipine, a widely used antihypertensive medication, has immunomodulatory effects that can enhance dendritic cell maturation and anti-tumor immunity. The study, published in Molecular Therapy, found that amlodipine promotes DC maturation, increases
Cancer
Researchers from Technological University Dublin have developed a new gene delivery vector, known as Hyperbranched poly(b-amino ester)s (HPAEs), which has shown superior functionalization potential and improved transfection efficacy in glioma cells. The vector, modified with tryptamine, has demonstrated enhanced transfection efficacy by 2-3-fold compared to unmodified HPAEs, while
Cancer
The Chemotherapy-Induced Febrile Neutropenia (CIN) pipeline is a rapidly growing area of research, with over four key companies actively developing more than four therapeutic candidates for CIN treatment. DelveInsight's "Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2025" report provides a comprehensive analysis of the ongoing clinical
Cancer
A new study published in the Lancet Primary Care journal found that patients with a positive stool test for bowel cancer symptoms had double the risk of death after one year compared to those with negative tests. The study, led by Professor David Humes at the University of Nottingham, analyzed
Cancer
Researchers from Anhui Medical University have made significant discoveries in the field of immunology and autoimmunity, highlighting the potential of Tyrosine Kinase 2 (TYK2) inhibitors in treating various autoimmune diseases and cancers. The study, published in Bioorganic Chemistry, explored the structure and biological features of TYK2, the JAK/STAT signaling
Cancer
Researchers from Universite Claude Bernard Lyon 1 have made a significant discovery in the field of cancer treatment. According to their study, published in the journal Biochimica et Biophysica Acta, the inhibition of nucleotide excision repair (NER) proteins can increase the efficacy of alkylating agents used to treat various cancers.
Cancer
Researchers at the Indian Institute of Technology Guwahati have published a comprehensive review on the diverse roles of protein iron transporters in oncogenesis. According to the study, iron transporters play a crucial role in sustaining cancer hallmark processes, such as proliferation, apoptosis evasion, metastasis, and resistance to therapy. The research
Cancer
A study published in the British Journal of Clinical Pharmacology has found that proton pump inhibitors (PPIs) are associated with shorter progression-free survival in patients with advanced gastric cancer receiving ramucirumab, a vascular endothelial growth factor receptor 2 (VEGFR2)-targeting monoclonal antibody, plus paclitaxel or nab-paclitaxel. Researchers from the University
